An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (NCT06047080)

🧪 Interventions in This Study

• Glofitamab (DRUG)
• Polatuzumab vedotin (DRUG)
• Rituximab (DRUG)
• Cyclophosphamide (DRUG)
• Doxorubicin (DRUG)
• Prednisone (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (229 Sites)

Showing the first 25 of 229 sites.

• Alaska Oncology & Hematology, LLC — Anchorage, Alaska
• Kaiser Permanente - Anaheim (E. La Palma) — Anaheim, California
• University of California, San Francisco-Fresno — Clovis, California
• City of Hope National Medical Center — Duarte, California
• City of Hope - Lennar Foundation Cancer Center — Irvine, California
• Valkyrie Clinical Trials — Los Angeles, California
• UCLA Jonsson Comprehensive Cancer Center — Los Angeles, California
• Kaiser Permanente - Roseville — Roseville, California
• Kaiser Permanente - Santa Clara — Santa Clara, California
• Stanford Univ School of Med — Stanford, California
• Kaiser Permanente Medical Ctr — Vallejo, California
• University of Colorado Cancer Center — Aurora, Colorado
• Rocky Mountain Cancer Center - Denver — Littleton, Colorado
• Yale University School Of Medicine — New Haven, Connecticut
• Medstar Franklin Square Medical Center — Washington D.C., District of Columbia
• Miami Cancer Institute of Baptist Health, Inc. — Miami, Florida
• Memorial Cancer Institute at Memorial West — Pembroke Pines, Florida
• Hawaii Cancer Care — Honolulu, Hawaii
• Robert H. Lurie Comprehensive Cancer Center of Northwestern University — Chicago, Illinois
• Illinois Cancer Care — Peoria, Illinois
• Springfield Clinic — Springfield, Illinois
• University of Iowa — Iowa City, Iowa
• Ascension Via Christi Research — Wichita, Kansas
• Ochsner Medical Center — New Orleans, Louisiana
• Massachusetts General Hospital — Boston, Massachusetts

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Large B-Cell Lymphoma

• Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma — Mobile, Alabama
• Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma — St Louis, Missouri
• Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas — Cleveland, Ohio
• Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma — Houston, Texas
• CAR-T Followed by Bispecific Antibodies — Omaha, Nebraska

Explore by condition: All Large B-Cell Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.